Palvella Therapeutics (PVLA) Prepaid Assets (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Prepaid Assets of $1.4 million for Q1 2026, down 24.9% year-over-year from $1.8 million in Q1 2025, and up 37.11% quarter-over-quarter from $1.0 million in Q4 2025.
Palvella Therapeutics (PVLA) Prepaid Assets (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Prepaid Assets for 14 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 24.9% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (down 24.9% YoY), while the FY2025 annual figure was $1.0 million, down 56.23% from the prior year.
- Prepaid Assets advanced to $1.4 million in Q1 2026 per PVLA's latest filing, from $1.0 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $11.1 million in Q1 2023 and bottomed at $198000.0 in Q4 2023.
- Historically, Prepaid Assets has averaged $4.3 million across 5 years, with a median of $2.3 million in 2024.
- On a YoY basis, Prepaid Assets climbed as much as 1059.6% in 2024 and fell as far as 96.94% in 2024.
- Palvella Therapeutics' Prepaid Assets stood at $3.2 million in 2022, then slumped by 93.84% to $198000.0 in 2023, then surged by 1059.6% to $2.3 million in 2024, then plunged by 56.23% to $1.0 million in 2025, then soared by 37.11% to $1.4 million in 2026.
- Business Quant data shows PVLA's Prepaid Assets at $1.4 million in Q1 2026, $1.0 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.44 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Sep 30, 2024 | 280,000.00 |
| Jun 30, 2024 | 649,000.00 |
| Mar 31, 2024 | 2.97 Mn |
| Dec 31, 2023 | 198,000.00 |
| Sep 30, 2023 | 9.15 Mn |
| Jun 30, 2023 | 10.65 Mn |
| Mar 31, 2023 | 11.07 Mn |
| Dec 31, 2022 | 3.21 Mn |
| Sep 30, 2022 | 7.91 Mn |
| Jun 30, 2022 | 8.70 Mn |
| Mar 31, 2022 | 9.84 Mn |
| Dec 31, 2021 | 6.55 Mn |
| Sep 30, 2021 | 5.95 Mn |